Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis.

Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis.

Lung pathology in cystic fibrosis is linked to dehydration of the airways epithelial surface which in part results from inappropriately raised sodium reabsorption through the epithelial sodium channel (ENaC). To identify a small-interfering RNA (siRNA) which selectively inhibits ENaC expression, che...

Full description

Bibliographic Details
Main Authors: Clark, K, Hughes, SA, Bulsara, P, Coates, J, Moores, K, Parry, J, Carr, M, Mayer, R, Wilson, P, Gruenloh, C, Levin, D, Darton, J, Weber, WM, Sobczak, K, Gill, DR, Hyde, S, Davies, L, Pringle, I, Sumner-Jones, S, Jadhav, V, Jamison, S, Strapps, W, Pickering, V, Edbrooke, MR
Format: Journal article
Language:English
Published: 2013

Similar Items